208 related articles for article (PubMed ID: 36211958)
1. Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a
Barroso DH; Gonçalves RT; Barbosa JS; da Motta JOC; Freire GSM; Gomes CM; Sampaio RNR
Front Cell Infect Microbiol; 2022; 12():993338. PubMed ID: 36211958
[TBL] [Abstract][Full Text] [Related]
2. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
[TBL] [Abstract][Full Text] [Related]
3. Interventions for American cutaneous and mucocutaneous leishmaniasis.
Pinart M; Rueda JR; Romero GA; Pinzón-Flórez CE; Osorio-Arango K; Silveira Maia-Elkhoury AN; Reveiz L; Elias VM; Tweed JA
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD004834. PubMed ID: 32853410
[TBL] [Abstract][Full Text] [Related]
4. A retrospective cohort study of the effectiveness and adverse events of intralesional pentavalent antimonials in the treatment of cutaneous leishmaniasis.
Rodrigues BC; Ferreira MF; Barroso DH; Motta JOCD; Paula CDR; Porto C; Martins SS; Gomes CM; Sampaio RNR
Int J Parasitol Drugs Drug Resist; 2020 Dec; 14():257-263. PubMed ID: 33285343
[TBL] [Abstract][Full Text] [Related]
5. Treatment of imported New World cutaneous leishmaniasis in Germany.
Harms G; Scherbaum H; Reiter-Owona I; Stich A; Richter J
Int J Dermatol; 2011 Nov; 50(11):1336-1342. PubMed ID: 22004484
[TBL] [Abstract][Full Text] [Related]
6. Atypical manifestations of tegumentary leishmaniasis in a transmission area of Leishmania braziliensis in the state of Bahia, Brazil.
Guimarães LH; Machado PR; Lago EL; Morgan DJ; Schriefer A; Bacellar O; Carvalho EM
Trans R Soc Trop Med Hyg; 2009 Jul; 103(7):712-5. PubMed ID: 19481233
[TBL] [Abstract][Full Text] [Related]
7. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate.
Romero GA; Guerra MV; Paes MG; Macêdo VO
Am J Trop Med Hyg; 2001 Nov; 65(5):456-65. PubMed ID: 11716098
[TBL] [Abstract][Full Text] [Related]
8. Disseminated Leishmaniasis, a Severe Form of Leishmania braziliensis Infection.
Machado PRL; Lago A; Cardoso TM; Magalhaes A; Carvalho LP; Lago T; Carvalho AM; Costa R; Carvalho EM
Emerg Infect Dis; 2024 Mar; 30(3):510-518. PubMed ID: 38407142
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G
J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
[TBL] [Abstract][Full Text] [Related]
10. American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure.
Marques SA; Merlotto MR; Ramos PM; Marques MEA
An Bras Dermatol; 2019 Jul; 94(3):355-357. PubMed ID: 31365669
[TBL] [Abstract][Full Text] [Related]
11. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.
Pimentel MI; Baptista C; Rubin EF; Vasconcellos Ede C; Lyra MR; Salgueiro Mde M; Saheki MN; Rosalino CM; Madeira Mde F; Silva AF; Confort EM; Schubach Ade O
Rev Soc Bras Med Trop; 2011; 44(2):254-6. PubMed ID: 21552747
[TBL] [Abstract][Full Text] [Related]
12. A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis.
Neves LO; Talhari AC; Gadelha EP; Silva Júnior RM; Guerra JA; Ferreira LC; Talhari S
An Bras Dermatol; 2011; 86(6):1092-101. PubMed ID: 22281895
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of safety and efficacy of topical liposomal amphotericin B for cutaneous leishmaniasis caused by Leishmania major in Islamic Republic of Iran.
Khamesipour A; Mohammadi A; Jaafari M; Eskandari S; Tasbihi M; Javadi A; Afshari F; Mortazavi H; Firooz A
East Mediterr Health J; 2022 Sep; 28(9):658-663. PubMed ID: 36205204
[TBL] [Abstract][Full Text] [Related]
14. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial.
Lago J; Fraga D; Guimarães LH; Lago T; Silva YJ; Lago E; Werneck GL; Bacellar O; Carvalho EM
PLoS Negl Trop Dis; 2023 Feb; 17(2):e0011064. PubMed ID: 36791065
[TBL] [Abstract][Full Text] [Related]
16. Effective meglumine antimoniate intralesional therapy for Chiclero's ulcer refractory to systemic liposomal amphotericin B.
Spinicci M; Zammarchi L; Gramiccia M; Di Muccio T; Bartolozzi D; Corsi P; Trotta M; Bartoloni A
J Travel Med; 2021 Aug; 28(6):. PubMed ID: 32918547
[No Abstract] [Full Text] [Related]
17. American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate.
Senchyna A; Simon S; Cissé H; Ginouves M; Prevot G; Alcoba G; Demar M; Couppie P; Blaizot R
Br J Dermatol; 2020 Aug; 183(2):389-391. PubMed ID: 32078162
[No Abstract] [Full Text] [Related]
18. Favorable responses to treatment with 5 mg Sbv/kg/day meglumine antimoniate in patients with American tegumentary leishmaniasis acquired in different Brazilian regions.
Cataldo JI; Conceição-Silva F; Antônio LF; Schubach AO; Marzochi MCA; Valete-Rosalino CM; Pimentel MIF; Lyra MR; Oliveira RVC; Barros JHDS; Pacheco RDS; Madeira MF
Rev Soc Bras Med Trop; 2018; 51(6):769-780. PubMed ID: 30517530
[TBL] [Abstract][Full Text] [Related]
19. Refractory mucocutaneous leishmaniasis resolved with combination treatment based on intravenous pentamidine, oral azole, aerosolized liposomal amphotericin B, and intralesional meglumine antimoniate.
Basile G; Cristofaro G; Locatello LG; Vellere I; Piccica M; Bresci S; Maggiore G; Gallo O; Novelli A; Di Muccio T; Gramiccia M; Gradoni L; Gaiera G; Bartoloni A; Zammarchi L
Int J Infect Dis; 2020 Aug; 97():204-207. PubMed ID: 32505874
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate.
Perez-Franco JE; Cruz-Barrera ML; Robayo ML; Lopez MC; Daza CD; Bedoya A; Mariño ML; Saavedra CH; Echeverry MC
PLoS Negl Trop Dis; 2016 May; 10(5):e0004739. PubMed ID: 27243811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
